People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $85.4M | $3.0B | 2016 |
| OmniAb, Inc. | — | Biotechnology | Series B | $30.0M | $130.5M | 2025 |
| Qualigen Therapeutics, Inc. | — | Biotechnology | Series A | $27.9M | $14.1M | 2018 |
| Viking Therapeutics, Inc. | — | Biotechnology | Seed | $3.7M | $162.3M | 2017 |
Matthew W. Foehr at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew W. Foehr on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Noah Doyle | 1 | 19 |
| Paul V. Maier | 1 | 6 |
| Braeden Lichti | 1 | 4 |
| Graydon Bensler | 1 | 4 |
| Andrew Ritter | 1 | 3 |
| Campbell Becher | 1 | 3 |
| Ira E. Ritter | 1 | 2 |
| Brian Lian | 1 | 2 |
| THOMAS ADAMEK | 1 | 2 |
| John L. Higgins | 1 | 2 |
| Kevin Richardson II | 1 | 2 |
| Ira Ritter | 1 | 2 |
| ANDREW J. RITTER | 1 | 1 |
| THOMAS J. ADAMEK | 1 | 1 |
| WILLIAMS LEE | 1 | 1 |
| MIKE J. STEP | 1 | 1 |
| IRA J. RITTER | 1 | 1 |
| Lee Williams | 1 | 1 |
| LEE J. WILLIAMS | 1 | 1 |
| STEVEN J. MARKOWITZ | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.